Results 71 to 80 of about 5,649 (188)

Wertorientierte Unternehmensführung bei RWE

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung, 2000
The main concept of performance measurement in the RWE-Group is a rate of return on invested capital. A positive spread between the rate of return on invested capital and the cost of capital rate is the main value driver. The required target-return on invested capital for business units is determined by a benchmark analysis.
openaire   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop

Frontiers in Pharmacology
Introduction: Real-world evidence (RWE) in health technology assessment (HTA) holds significant potential for informing healthcare decision-making. A multistakeholder workshop was organised by the European Health Data and Evidence Network (EHDEN) and the
Ravinder Claire, Jamie Elvidge, Shahid Hanif, Hannah Goovaerts, Peter R. Rijnbeek, Páll Jónsson, Karen Facey, Dalia Dawoud, Dalia Dawoud   +8 more
doaj   +1 more source

Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE)

Pediatric Dermatology, EarlyView.
ABSTRACT Background INTEGUMENT‐PED/NCT04845620, a 4‐week, phase 3 trial, demonstrated efficacy and safety of roflumilast cream 0.05% in children aged 2–5 years with mild‐to‐moderate atopic dermatitis (AD). A phase 3 open‐label extension trial (INTEGUMENT‐OLE [NCT04804605]) investigated long‐term outcomes continuing roflumilast cream for ≤ 56 weeks ...
Lawrence F. Eichenfield, Mercedes E. Gonzalez, Mark Boguniewicz, Tracy Funk, Adelaide A. Hebert, Vimal H. Prajapati, Chesahna Kindred, Rocco Serrao, Lisa Swanson, David Krupa, Scott Snyder, Melissa S. Seal, Diane Hanna, Patrick Burnett, David R. Berk   +14 more
wiley   +1 more source

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Bioengineering
The use of real-world data (RWD) for healthcare decision-making is complicated by concerns regarding whether RWD is fit-for-purpose or is of sufficient validity to support the creation of credible RWE.
Kelly H. Zou, Marc L. Berger
doaj   +1 more source

Do Just Energy Transition Partnerships collide or converge with substantive investment law standards? Case studies from Indonesia and Vietnam

Review of European, Comparative &International Environmental Law, EarlyView.
Abstract Just Energy Transition Partnerships (JETPs) are novel financing mechanisms that encourage coal‐dependent emerging economies to transition away from fossil fuels. JETPs aim to facilitate coal phaseout and transitions to renewable energy through private and public financing.
Francine Hug
wiley   +1 more source

Generalizability in real‐world trials

Clinical and Translational Science
Real‐world evidence (RWE) trials have a key advantage over conventional randomized controlled trials (RCTs) due to their potentially better generalizability.
Anatol‐Fiete Näher, Marvin Kopka, Felix Balzer, Matthias Schulte‐Althoff   +3 more
doaj   +1 more source

The Future of the Obesity Management Landscape: Challenges, Opportunities and Solutions

Obesity Science &Practice, Volume 12, Issue 2, April 2026.
ABSTRACT Objective In July 2023 a diverse group of international experts from academia, healthcare and medical technology/pharmacological companies gathered to discuss the current global landscape in the management of obesity, identify the clinical challenges healthcare systems are facing, and the gaps in scientific knowledge. Approach We proposed ways
Alexander Dimitri Miras, Alexander Kokkinos, Abd Tahrani, Ricardo Reynoso, Jörg Tomaszewski, Ildiko Lingvay, Domenica Rubino, Jonathan Q. Purnell, Muzamil Hussain, Amy Hall, Dimitrios Pournaras, Philip Schauer, Carel W. le Roux, Luiza Borowska, Chiedza Kaitano, Ishita Doshi, Dominique Gregoire, Helen Haggart, María Morán Gortaire, Stephanie Mutchler, Barbara Sleypen, Elena Startseva, Priya Sumithran, Francis M. Finucane   +23 more
wiley   +1 more source

Determining the Survival Impact and Cost‐Effectiveness of Multi‐Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches

Health Services Research, Volume 61, Issue 2, April 2026.
ABSTRACTObjectiveTo determine the effectiveness and cost‐effectiveness of multi‐gene panel sequencing compared to single‐gene KRAS testing for metastatic colorectal cancer (mCRC).Study Setting and DesignBritish Columbia, Canada (BC) is a provincial single‐payer public healthcare system, and it was the first province to publicly reimburse multi‐gene ...
Emanuel Krebs, Deirdre Weymann, Howard J. Lim, Stephen Yip, Dean A. Regier   +4 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source